(Q46937457)

26 December 2017

title

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma (English)

1 reference

26 December 2017

0 references

Junji Furuse

1

1 reference

26 December 2017

Hiroshi Ishii

2

1 reference

26 December 2017

Kohei Nakachi

3

1 reference

26 December 2017

Eiichiro Suzuki

4

1 reference

26 December 2017

Satoshi Shimizu

5

1 reference

26 December 2017

Keiko Nakajima

6

1 reference

26 December 2017

publication date

22 October 2007

1 reference

26 December 2017

published in

Cancer Science

1 reference

26 December 2017

volume

99

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

159-165

1 reference

26 December 2017

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

BAY 43-9006: preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

BAY 43-9006: early clinical data in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00648.X

10.1111/J.1349-7006.2007.00648.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017